CTRI/2017/06/008857进行中（未招募）未知
A randomized, multi center,openlabel,two-treatment, wo-period, two-sequence,multiple dose,crossover,steadystatebioequivalence study of Clozapinetablets25 mg ofChangzhou Pharmaceutical Factory,Chinavs.Clozaril@ 25mg Tablets, Distributed by:NovartisPharmaCorporation EastHanover,NJ 07936in adultschizophrenic patientsalreadyreceivingstable dailydoseof Clozapine 25mgtabletwicedailyunderfasting condition
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Men and women aged 18-65 years (both inclusive) having clinical diagnosis of schizophrenia (DSM IV-TR).
- •2.Patients have a diagnosis of treatment-resistant schizophrenia {Treatment resistance is defined as an inadequate response to at least two antipsychotic drugs at the maximally tolerated dose within the recommended therapeutic range in treatment lasting six weeks or more. Termination of a medication due to adverse events before reaching the appropriate dose and duration should not be regarded as a failed treatment due to non response to the medication.
- •3.Schizophrenic patients who are on stable dose of Clozapine 25 mg for at least 3 months prior to randomization and receiving Clozapine 25 mg twice daily.
- •4.Patients should be otherwise healthy as determined by physical examination, medical history, and routine hematologic and biochemical tests.
- •5.Willing and able to comply with housing, restrictions and other protocol requirements as indicated by signed written informed consent witnessed by a legally acceptable representative.
- •6.Females of childbearing potential (sexually active women who have not completed 1 year after menopause & have not gone through hysterectomy or bilateral tubal ligation) must have a negative pregnancy test (at screening and prior to check-in in Period I) as well as must be non-lactating at screening and must agree to use an effective contraceptive method during study.
- •7.No participation in any clinical study within the past 90 days.
排除标准
- •1.A history of allergic reactions to Clozapine / any of the component of study drug or other chemically related psychotropic drugs
- •2.Concurrent primary psychiatric disorder other than schizophrenia or neurological diagnosis, including organic mental disorder, neuroleptic malignant syndrome, severe tardive dyskinesia, or idiopathic Parkinsonâ??s disease and dementia related psychosis, a history of epilepsy or other predisposing risk factors for seizures, history of multiple syncopal attacks or any other clinically significant CNS disorder.
- •3.Patients with the following cardiac conditions:
- •Recent myocardial infarction ( <12 months)
- •QTc prolongation (screening electrocardiogram with QTc >450 msec for men, QTc >470 msec for women)
- •History of QTc prolongation or using concomitant medications which prolong QTc interval.
- •Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia
- •Uncompensated congestive heart failure, myocarditis, cardiomyopathy
- •Complete left bundle branch block
- •First-degree heart block with PR interval > 0.22 seconds
- •4.Patients with significant renal or hepatic impairment in which dose reduction is necessary as per the clinical evaluation of the patient by the Investigator.
- •5.Patients with narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic medications are required for the treatment, paralytic ileus, intestinal obstruction etc.
- •6.Patients with known history of CYP2D6 poor metabolizers.
- •7.A history of granulocytopenia/ agranulocytosis or myeloproliferative disorders (drug-induced or idiopathic)
- •8.Patient with the history or presence of orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing) at the time of screening.
- •9.Concurrent use of antihypertensive medication or any medication that might pre¬dispose to orthostatic hypotension
- •10.A medical or surgical condition that might interfere with the absorption, metabolism, or excretion of Clozapine
- •11.Any of the following hematological abnormality at screening
- •Total white blood cell count < 4000/c.mm
- •Absolute neutrophil count < 2000/c.mm
- •Absolute eosinophil count > 700 / c.mm
- •Patients with poor glycemic control as defined by HbA1c >=7% and/or fasting blood glucose >160 mg/dL at screening
- •Patients with total cholesterol >300 mg/dL and triglycerides level > 300 mg/dL at screening
- •12.Concurrent use of other drugs known to suppress bone marrow function
- •13.Expected changes in concomitant medications during the period of study.
- •14.Positive tests for drug or alcohol abuse at screening or baseline.
- •15.A history of alcohol or drug dependence by Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria during the 6-month period immediately prior to study entry.
- •16.History of multiple syncopal episodes.
- •17.Patients have a history of narrow-angle glaucoma
- •18.Use of any of the following medications within14 days or at least five half lives have not been passed between last dose of the previous medication and first dose of the study medication, preceding enrolment including but not limited to:
研究者
相似试验
尚未招募
不适用
A study to compare absorption of the test drug - Tab Felbamate 600 mg with that of the approved drug - Tablet Felbatol (Felbamate 600,in patients of partial epilepsy not responding to therapy.CTRI/2014/05/004600annett Company Inc38
已完成
不适用
A Clinical Trial to study the clinical bioequivalence of Clozapine 100 mg tablet of Aurobindo in comparison to Clozaril® (Clozapine) 100 mg tablet of Novartis in patients suffering from SchizophreniaCTRI/2013/06/003745Aurobindo Pharma Limited36
进行中（未招募）
不适用
To compare the bioavailability of Olaparib tablets 150 mg of Qilu Pharmaceutical (Hainan) Co., Ltd. with LYNPARZA® (Olaparib) tablets 150 mg of AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850.CTRI/2023/01/048872Qilu Pharmaceutical Co., Ltd.
招募中
不适用
To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulationsCTRI/2012/08/002940Hetero Labs Ltd64
已完成
不适用
To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations.CTRI/2012/07/002778Hetero Labs Ltd64